← Leaderboards
Worapol Ngamcherdtrakul
Pdx Pharmaceuticals, Inc.
$4,005,298
Attributed
$9,153,298
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.3M · FY2017–25$2.5M$1.9M$1.3M$625K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,153,298 · 6
By mechanism
R44$8,578,298 · 4
R43$325,000 · 1
SB1$250,000 · 1
Top collaborators
- Wassana Yantasee16 shared
- Joe W. Gray4 shared
- Moataz Reda3 shared
Others in their field
Other Emerging Leaders on “Nanoparticle”
- Bala Raja · Luminostics, Inc.$28,624,460
- Scott Fry$21,470,000
- Jay Evans · University Of Montana$20,430,088
- Neil King · University Of Washington$14,428,723
- Norbert Pardi · University Of Pennsylvania$12,463,043
- Timothy Fouts · Advanced Bioscience Laboratories, Inc.$12,343,878
Research focus
NanoparticleLeadCell DeathSmall Business Innovation Research GrantCellsDoseSuccessSafetyMalignant NeoplasmsImmuneCancer CellTumorMouse ModelSpecificityIn VivoSmall Interfering RnaAntibodiesToxic EffectNanotherapeuticCessation Of LifeResistanceParticle SizePharmaceutical PreparationsBenchmarking
Grant awards (16)
PLK1 and EGFR targeted nanoconstruct as a monotherapy and a radiation sensitizer for lung cancer$1,288,251
R44 · FY2025 · CA · contact PI
Advancing the commercialization readiness of nanoparticle-based immunotherapy for cancer treatment$89,348
SB1 · FY2025 · CA · contact PI
Novel Nano-immunotherapy for Treatment of Non-small Cell Lung Cancer$932,751
R44 · FY2024 · CA · contact PI
PLK1 and EGFR targeted nanoconstruct as a monotherapy and a radiation sensitizer for lung cancer$914,249
R44 · FY2024 · CA · contact PI
Advancing the commercialization readiness of nanoparticle-based immunotherapy for cancer treatment$160,652
SB1 · FY2024 · CA · contact PI
Novel Nano-immunotherapy for Treatment of Non-small Cell Lung Cancer$932,751
R44 · FY2023 · CA · contact PI
PLK1 and EGFR targeted nanoconstruct as a monotherapy and a radiation sensitizer for lung cancer$400,000
R44 · FY2023 · CA · contact PI
In Situ Tumor Vaccination with a Nano-oligo Therapeutic to Induce Whole-body Antitumor Immune Response$101,639
R44 · FY2022 · CA · contact PI
In Situ Tumor Vaccination with a Nano-oligo Therapeutic to Induce Whole-body Antitumor Immune Response$1,898,361
R44 · FY2021 · CA · contact PI
Novel Nano-immunotherapy for Treatment of Non-small Cell Lung Cancer$378,030
R44 · FY2021 · CA · contact PI
Nanoparticle-based targeted codelivery of siRNA and taxane to treat drug-resistant HER2+ breast cancer$513,354
R44 · FY2019 · CA · contact PI
Nanoparticle-based targeted codelivery of siRNA and taxane to treat drug-resistant HER2+ breast cancer$233,858
R44 · FY2019 · CA · contact PI
Supplement grant for R44CA217534: Nanoparticle-based targeted codelivery of siRNA and taxane to treat drug-resistant HER2+ breast cancer$14,938
R44 · FY2019 · CA · contact PI
Nanoparticle-based targeted codelivery of siRNA and taxane to treat drug-resistant HER2+ breast cancer$745,151
R44 · FY2018 · CA · contact PI
Development of topical formulation of siRNA-nanoparticle for treating skin diseases$325,000
R43 · FY2017 · TR · contact PI
Nanoparticle-based targeted codelivery of siRNA and taxane to treat drug-resistant HER2+ breast cancer$224,965
R44 · FY2017 · CA · contact PI